Maria Guseva

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Peter H. O’Donnell, Matthew I. Milowsky, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2023 · 157 citations · Full text

Dietary Choline Supplementation Improves Behavioral, Histological, and Neurochemical Outcomes in a Rat Model of Traumatic Brain Injury

Maria Guseva, Deann M. Hopkins, Stephen W. Scheff et al. · Journal of Neurotrauma · 2008 · 96 citations · Full text

LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)

Jonathan E. Rosenberg, M. Milowsky, Chethan Ramamurthy et al. · Annals of Oncology · 2022 · 38 citations

Metastatic Urothelial Cancer, Urology, Genitourinary Cancer +8

Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.

Daniel P. Petrylak, Thomas W. Flaig, Nataliya Mar et al. · Journal of Clinical Oncology · 2022 · 26 citations

Radical Cystectomy, Surgical Oncology, Antitumor Activity +16

An autoradiographic analysis of rat brain nicotinic receptor plasticity following dietary choline modification

Maria Guseva, Deann M. Hopkins, James R. Pauly · Pharmacology Biochemistry and Behavior · 2006 · 24 citations · Full text

Neuroanatomy, Medicine, Physiology +10